Richard Burr: “Senator Burr's bill, S. 277 is a step in the right direction in rectifying this tragic situation.”

Ms. Kotagal's refusal to continue these common-sense measures speaks volumes of her lack of commitment to due process and transparency.

Without Orrin, we wouldn't have a generic drug industry.

Are you beginning to see the pattern as to why a plan is important? This has been a well-orchestrated event up to this point.

I question whether the agreements both passed and proposed reflect a good deal for patients they are designed to serve.